

**TM STONEHAGE FLEMING  
AIM FUND**

PREVIOUSLY KNOWN AS TM CAVENDISH AIM FUND



**ACTIVELY  
MANAGED**



**STOCK PICKING  
APPROACH**



**LONG-TERM  
INVESTMENT HORIZONS**



**NAVIGATING TO INVESTMENTS  
WITH CLEAR STRATEGIES**



**GROWTH  
MINDSET**


**INVESTMENT OBJECTIVE**

The fund aims to achieve long-term capital growth.

**INVESTMENT POLICY**

The Fund aims to invest mainly in equities on the UK Alternative Investment Market ('AIM'). This will be achieved by an actively managed diversified portfolio of shares spread across any sector of AIM. In addition, the Fund may on occasion invest in fully listed shares of companies with smaller market capitalisations.

**PORTFOLIO PERFORMANCE**



■ TM Stonehage Fleming AIM Fund B ■ Numis Alternative Markets Index

**STANDARDISED FUND PERFORMANCE (%)**

Performance	3m	6m	YTD	1yr	3yrs	5yrs
TM Stonehage Fleming AIM Fund B	-3.9	0.6	27.1	27.1	93.2	138.1
Numis Alternative Markets Index	-1.3	-1.5	7.6	7.6	47.3	54.9
IA UK Smaller Companies Peer Group Percentile	86	71	23	23	3	7

**DISCRETE 12 MONTH PERFORMANCE (%)**

12 months to 31 December	2021	2020	2019	2018	2017
TM Stonehage Fleming AIM Fund B	27.1	11.2	36.7	-7.2	32.8
Numis Alternative Markets Index	7.6	19.3	14.7	-17.5	27.4
IA UK Smaller Companies Peer Group Percentile	23	24	11	22	18

**CALENDAR YEAR PERFORMANCE (%)**

Performance	2021	2020	2019	2018	2017	2016
TM Stonehage Fleming AIM Fund B	27.1	11.2	36.7	-7.2	32.8	31.4
Numis Alternative Markets Index	7.6	19.3	14.7	-17.5	27.4	16.3

Source: Morningstar as at 31/12/2021, % growth, total return, GBP, single price, UK net income reinvested with no initial charges.

**PERFORMANCE DISCLOSURE**

Past performance is not a guide to future performance. The value of investments can fall. Investors may not get back the amount invested. Income from investments may vary and is not guaranteed. For a full list of risks applicable to this fund, please refer to the Prospectus. If the information is not displayed in your base currency, then the return may increase or decrease due to currency fluctuations. Source for all performance is Stonehage Fleming Investment Management Limited as at 31 December 2021. Total return (with dividends) is net of fees.

*The fund invests in a broad range of AIM listed companies and some of these carry a higher risk of failure and may be less liquid than shares listed on other exchanges. These shares may be also harder to sell quickly because of this lower liquidity. AIM listed companies may also experience greater price volatility which could also affect the value of the fund.*

**KEY FACTS**

Launch Date	5 October 2005
IA Sector	UK Smaller Companies
Fund Size	£133.5m
Dealing Frequency	Daily

**FEES**

Initial Charge	Up to 5.00%
Ongoing Charges Figure (OCF) <sup>2</sup>	0.67%
Annual Management Charge	0.60%

<sup>2</sup> The OCF is the management fee plus additional fund expenses (excluding transaction costs) as a percentage of the assets of the fund. This gives an indication of annual expenses which may vary over time.

**MINIMUM INVESTMENT**

Lump Sum	£50,000
Additional	£5,000
Regular Savings	N/A

**FUND MANAGER**



**PAUL MUMFORD**

Paul Mumford has extensive investment experience. Having worked initially as an Analyst for Norris Oakley Brothers and later as a smaller companies expert at R Nivison, he moved to fund management in 1988 when he joined Glenfriars. He then joined Cavendish Asset Management at the group's formation in 1994. The acquisition of Cavendish Asset Management was made by Stonehage Fleming in July 2020. Paul is the co-manager of the TM Stonehage Fleming Aim Fund and the TM Stonehage Fleming Opportunities Fund.



**NICK BURCHETT**

Nick Burchett began his career in 1983 at Strauss Turnbull and subsequently joined W.I. Carr in 1990 which later became Investec Wealth & Investment after a number of mergers and acquisitions. During this period Nick dealt extensively with Paul Mumford on the analysis of UK equities, markets and execution factors. This partnership made a compelling proposition and after 27 years at Investec he joined Cavendish Asset Management in November 2017 to jointly manage the funds. The acquisition of Cavendish Asset Management was made by Stonehage Fleming in July 2020. Nick is the co-manager of the TM Stonehage Fleming Aim Fund and the TM Stonehage Fleming Opportunities Fund.

**AWARDS**



**TM STONEHAGE FLEMING  
AIM FUND**

PREVIOUSLY KNOWN AS TM CAVENDISH AIM FUND

**ENQUIRIES**

<b>ENQUIRIES AND DEALING</b>	
0333 300 0375	
(press 1 for Enquiries, press 2 for Dealing)	
<b>DEALING:</b>	
Thesis Unit Trust Management Limited, PO Box 3733, Royal Wootton Bassett, Swindon, SN4 4BG	
<b>SEDOL CODES:</b>	
Class B Share	B0JX3Z5
<b>ISIN CODES:</b>	
Class B Share	GB00B0JX3Z52
<b>LIPPER IDS:</b>	
Class B Share	65009655

**SECTOR ALLOCATION (%)\***

Health Care	23.1
Information Technology	23.0
Industrials	19.9
Energy	11.5
Consumer Discretionary	6.5
Communication Services	5.9
Materials	3.9
Real Estate	2.4
Consumer Staples	2.0
Cash	1.8

**TOP TEN HOLDINGS (%)\***

Beximco Pharmaceuticals GDR regs	3.4
Independent Oil & Gas Plc	3.4
Totally Plc	3.3
Serice Energy Plc	2.9
Eagle Eye Solutions Group Plc	2.6
Kistos Plc	2.4
ZOO Digital Group Plc	2.3
Lok'nStore Group Plc	2.2
M&C Saatchi Plc	2.2
Netcall Plc	2.1

Source: Thesis Unit Trust Management Limited and Stonehage Fleming Investment Management as at 31 December 2021. Third parties whose data may be included in this document do not accept any liability for errors or omissions.

**PORTFOLIO COMMENTARY**

The Numis Alternative Markets (incl. Investment Companies) Index increased by 2.7% in the month and underperformed the rest of the market which showed a greater appreciation. It was pleasing that the TM Stonehage Fleming AIM Fund saw its value advance by 3.5%. Part of this performance will be attributed to an overweight position in the energy sector where share prices performed well on the back of strong oil and gas prices. We also saw the emergence of takeover activity for our holding in Clinigen which promotes and licenses pharmaceuticals. Otherwise, there was limited news flow from our holdings where the majority have December year ends.

It is encouraging that although December can be a quiet month for AIM shares, there was a firm undertone and there was still the opportunity to add to a number of shares which had underperformed but were attractive on fundamental considerations. An example of this was Trackwise, where we added to our holding in a deeply discounted share placing to raise working capital to finance potential orders to install its printed circuit technology products in electric vehicles. A new holding added was CT Automotive, an IPO of a company which manufactures interior products such as dashboard vents and cup holders supplied to a large number of global car manufacturers with a variety of different models. To raise funds we disposed of our holding in Blue Prism, which was subject to an aggressive takeover, and FRP, the corporate adviser where much of the short term potential seemed to be reflected in the current share price.

**IMPORTANT INFORMATION**

This is a marketing communication issued by Stonehage Fleming Investment Management Limited (SFIM). SFIM is the investment manager of the Fund.

All investments risk the loss of capital. No guarantee or representation is made that the funds will achieve their investment objective.

The value of investments may go down as well as up. For products designed to return income, the distributions can also go down or up and you may not receive back the full value of your initial investment.

Derivatives have not been used but are allowed if appropriate for efficient asset management. The Fund only invests in UK assets but is allowed to hold shares on overseas exchanges. This would occur in the event of a company delisting from the London stock market and would not be expected to be material. Hence, there would be limited foreign exchange risk.

Past performance is not a guide to future returns. If the information is not displayed in your base currency, then the return may increase or decrease due to currency fluctuations.

The distribution or possession of this document in jurisdictions outside the United Kingdom may be restricted by law or other regulatory requirements.

For details of the Funds investment policy, please see the Investment Objective and Policy section of the Fund Prospectus Document.

The notable events in the month were the rise in inflation, the unexpected increase in interest rates and measures to combat the rapid spread of the Omicron strain of the Coronavirus. Fortunately, none of these seem to have had an adverse effect on the equity market. Some measures were taken to safeguard the spread of Omicron, and the country was not put into a full lockdown. It was recognised that the effects were not as serious as previous variants given full vaccination levels and booster jabs being administered to the population. Equally, the small increase in interest rates appears to not have a material impact on the economy. Inflationary pressures could have a greater impact, but most companies accept that the rises in energy and other input costs can potentially be offset, and some of the rises are passed on to customers. The rise in wage restraint should add to higher inflation as companies try to maintain margins, and we are mindful of the possible negative impact on some areas of industry.

Despite a mild winter, the high level of energy prices persists, with share prices in the oil and gas sector not fully accounting for the rise in earnings and cash flow which may now be expected. We feel comfortable with our exposure to the sector and feel that exciting prospects remain with the rest of the portfolio. Our exposure to the IT and healthcare sectors gives us confidence in the outlook. Although several uncertainties remain, we would look for a further recovery in the global and domestic economies and, moving forward, are positive that the fund is well positioned for whatever lies ahead.

Whilst every effort is made to ensure that the information provided to clients is accurate and up to date, some of the information may be rendered inaccurate by changes in applicable laws and regulations may be subject to change in the future.

The information in this document does not constitute legal, tax, or a personal recommendation.

The Fund is authorised in the United Kingdom and regulated by the Financial Conduct Authority.

The Authorised Fund Manager is Thesis Unit Trust Management Limited, Exchange Building, St John's Street, Chichester, West Sussex, PO19 1UP. Authorised and regulated by the Financial Conduct Authority.

Before you invest you should read the Key Investor Information Document (KIID) and the Prospectus which contain detailed information. These documents are available in English, free of charge, upon request by writing to Thesis Unit Trust Management Limited at Exchange Building, St John's Street, Chichester, West Sussex PO19 1UP; or by phoning 01483 783 900 between 9am and 5pm Monday to Friday; or on the website at [www.fundlistings.com](http://www.fundlistings.com).

© Stonehage Fleming Investment Management Limited 2022